Milu Labs
Milu Labs develops noninvasive diagnostic tests that give clinicians early, actionable risk assessments for women's health, including preterm birth. The company combines exosome-based biomarkers and multiomics (proteome, transcriptome, epigenome, microbiome) with artificial intelligence to generate predictive “bio-fingerprints.” Milu Labs operates as a diagnostics and B2B SaaS provider, delivering subscription-based clinical tests and analytics to healthcare providers while its tests inform care for individual patients. The company partners with academic researchers and clinicians and focuses on commercializing solutions for Asia and global markets.
Milu Labs
Milu Labs develops noninvasive diagnostic tests that give clinicians early, actionable risk assessments for women's health, including preterm birth. The company combines exosome-based biomarkers and multiomics (proteome, transcriptome, epigenome, microbiome) with artificial intelligence to generate predictive “bio-fingerprints.” Milu Labs operates as a diagnostics and B2B SaaS provider, delivering subscription-based clinical tests and analytics to healthcare providers while its tests inform care for individual patients. The company partners with academic researchers and clinicians and focuses on commercializing solutions for Asia and global markets.